Next Article in Journal
Iontophoresis: A Potential Emergence of a Transdermal Drug Delivery System
Previous Article in Journal
Scientia Pharmaceutica, Autorenhinweise 2010
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessArticle
Sci. Pharm. 2013, 81(3), 763-776; https://doi.org/10.3797/scipharm.1307-09 (registering DOI)

Nitric Oxide is a Potential Diagnostic Marker for Hepatocellular Carcinoma

1
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt
2
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. 2 Oncology Center, Mansoura University, Mansoura, 35516, Egypt
3
Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt
*
Author to whom correspondence should be addressed.
Received: 12 July 2013 / Accepted: 8 August 2013 / Published: 8 August 2013
PDF [270 KB, uploaded 29 September 2016]

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh most common in women. This cancer varies widely in incidence throughout the world, with rising incidence in Egypt. HCC is considered the second most frequent cause of cancer incidence and mortality among men in Egypt. This study aimed to estimate the serum levels of nitric oxide (NO) and glutathione reductase in order to evaluate their role as oxidative status markers in HCC development and progression. For this purpose, serum levels of these parameters were assessed in 50 HCC patients, and 30 cirrhotic patients in addition to 15 healthy subjects as a control group. In the present study, glutathione reductase activity showed a significant increase in HCC as compared to the control group (P= 0.019). On the other hand, no significant difference was observed between the cirrhotic and HCC patients (P= 0.492). Serum NO was significantly higher in patients with HCC than in cirrhotic patients (P= 0.001) or the control group (P= 0.001), with a sensitivity of (74%) and specificity of (88.89%) at a cut-off level of 614.1 μmol/l. While AFP, alpha-fetoprotein, at a cutoff level of 200 ng/ml had a sensitivity of (52%), the specificity was (100%). Indeed, nitric oxide was high in 62.5% of AFP-negative HCC patients. In conclusion, glutathione reductase has no role in HCC diagnosis. However, nitric oxide is a potential diagnostic marker for HCC. The simultaneous determination of serum nitric oxide and AFP gave significant improvement in the detection of HCC patients compared to that of AFP alone.
Keywords: Nitric oxide; Glutathione reductase; Hepatocellular carcinoma; Alpha-fetoprotein Nitric oxide; Glutathione reductase; Hepatocellular carcinoma; Alpha-fetoprotein
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

EISSA, L.A.; EISA, N.H.; EBRAHIM, M.A.; RAGAB, M.; EL-GAYAR, A.M. Nitric Oxide is a Potential Diagnostic Marker for Hepatocellular Carcinoma. Sci. Pharm. 2013, 81, 763-776.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top